SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-073573
Filing Date
2024-08-29
Accepted
2024-08-29 08:46:20
Documents
48
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0212637-6k_canfite.htm   iXBRL 6-K 23502
2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2024 ea021263701ex99-1_canfite.htm EX-99.1 83305
3 UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 202 ea021263701ex99-2_canfite.htm   iXBRL EX-99.2 309002
4 PRESS RELEASE DATED AUGUST 29, 2024 ea021263701ex99-3_canfite.htm EX-99.3 61369
  Complete submission text file 0001213900-24-073573.txt   2797838

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE canf-20240630.xsd EX-101.SCH 36603
6 XBRL CALCULATION FILE canf-20240630_cal.xml EX-101.CAL 22001
7 XBRL DEFINITION FILE canf-20240630_def.xml EX-101.DEF 142304
8 XBRL LABEL FILE canf-20240630_lab.xml EX-101.LAB 302158
9 XBRL PRESENTATION FILE canf-20240630_pre.xml EX-101.PRE 148630
51 EXTRACTED XBRL INSTANCE DOCUMENT ea0212637-6k_canfite_htm.xml XML 247851
Mailing Address 26 BEN GURION STREET RAMAT GAN L3 5257346
Business Address 26 BEN GURION STREET RAMAT GAN L3 5257346 972 39241114
Can-Fite BioPharma Ltd. (Filer) CIK: 0001536196 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36203 | Film No.: 241258945
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)